Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
-
On track to announce topline results from ORIGIN 3 trial in Q2 2025
- Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024
- 計劃在2025年第二季度公佈ORIGIN 3試驗的最終結果
- 預計在2024年第四季度展示atacicept在IgAN的ORIGIN Phase 2臨床試驗的96週數據
BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR primary efficacy endpoint, supporting the subsequent submission for regulatory approval.
加州布里斯班，2024年9月12日，Vera Therapeutics, Inc.（納斯達克股票代碼：VERA）宣佈已提前完成IgAN患者ORIGIN 3關鍵的III期atacicept試驗的初級終點的招募，該試驗的初始隊列中共有200名參與者，將提供爲期36周的UPCR主要療效終點數據，以支持隨後的監管批准遞交。
